


## Specialized Pro-resolving Mediators in real world clinical practice GRAND ROUNDS

Cory Rice, DO Dallas, TX


# Chronic Inflammation leads to many chronic diseases



Handschin C, Spiegelman BM. The role of exercise and PGC1alpha in inflammation and chronic disease. *Nature*. 2008 24;454(7203):463-9.




## Multi-step process of acute inflammation and resolution



Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. *Nature*. 2014;510(7503):92-101. Spite M, Clària J, Serhan CN. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. *Cell Metab*. 2014;19(1):21-36.



## Incorporating SPMs into clinical practice for patients with chronic inflammation



for Clinical Nutrition

## Recommended patient assessment tools: Evaluate initial presentation and track follow up progress

Clinically measureable biomarkers of inflammation including:

- hsCRP
- TNF-alpha
- Ferritin
- ESR
- Fibrinogen

Condition-specific questionnaires and quality of life forms including:

- Brief Pain Inventory
- American Chronic Pain Association Quality of Life Scale
- SF-12


Symptomatic measurement scales:

• MSQ/HSQ



## Case #1 41 year old Caucasian female: Stay-at-home mom, part-time student





Past medical & drug history Initial labs and tests

Management plan Week 4 followup

Week 4 followup

#### **Complaints:**

- Daily pain for last 8 months
  - R knee
  - Lankle
  - L shoulder for last 8 months
- Pain rating 5-6/10

#### On Examination:

- Height: 5'6"
- Weight: 194.8 lbs
- BMI: 31.4 kg/m<sup>2</sup>
- BP: 124/76 mm Hg
- Pulse: 99/min regular
- Temp: 98.9 (F) (mildly febrile)

Tot



Profile history & examination

Past medical & drug history Initial labs and tests

Management plan

Week 4 followup

#### **Current therapy:**

 Alternating ibuprofen and acetaminophen every 6 hours

#### **Past treatments:**

· Oral and injected steroids


Recommended methotrexate by rheumatologist which she refused

#### **Past Medical History:**

• Diagnosed with RA (earlier in 2015)

#### **Family Medical History:**

- Father: died; lung cancer
- Mother: died; heart disease
- Sisters: T2DM, pre-diabetes and psychiatric disease






	ofile history examination	Past me drug h		iitial labs an tests	d Managen plan		Week 4 follow- up	
	Brief Pain	Inventory						
				ge Pain in 24 hours	Pain now	<b>Scale:</b> 1 – no pain		1 P
	6	3		5	6	10 –	pain as bad as you car imagine	U
	Brief Pain Inventory							
In			ch has pain ir es not interfe		your: mpletely interfe	eres)		
	General activities	Mood	Walking	Normal wo	rk Relations to others	Slee	p Enjoyment of life	
	9	6	8	8	6	6	8	
	American Chronic Pain Association Quality of Life Scale							
		5						
<ul> <li>Struggles but fulfills daily</li> <li>No outside activity</li> <li>Not able to volunteer or w</li> </ul>				tivity		S		









Profile history & examination

Past medical & drug history

Initial labs and tests

Management plan Week 4 followup

## **Presentation:**

- Patient reports improvement
  - R knee pain no longer constant, only with walking
  - L foot pain no longer constant
  - L shoulder minor pain in certain positions not constant and no restriction of movement

#### **Current therapy:**

• SPMs 6 soft gels/day

## **On Examination:**


- Temp: 98.6
- BP: 120/74 mm Hg
- Pulse: 87/min regular
- Weight: 194 lbs
- BMI: 31.31 kg/m<sup>2</sup>

## Additional notes:


- Reduced overall pain
- Patient appears 'brighter' and better
- Reduced 'achiness'
- Reports less cravings for junk food

#### Management plan:

- Increase SPMs to 8 soft gels/day
  - Taper to maintenance dose of ~2 soft gels/day
- Continue to watch for and avoid dietary and environmental triggers of inflammation
  - obesity, body composition, glucose control, dietary sources, leaky gut, allergy, Infection
  - Utilize anti-inflammatory strategies as needed










Profile history & examination			Initial labs an tests	nd Manage plar		ek 4 follow- up		
Brief Pain Worst Pain in	-	in in Av	erage Pain in		Scale:			
past 24 hour		st 24 hours past 24 hours		Pain now 4	10 – pain as bad		is you can	
In past 24-ho	Brief Pain Inventory In past 24-hours how much has pain interfered in your: • Scale from 1 (does not interfere) to 10 (completely interferes)							
General activities	Mood	Walking	g Normal we	ork Relations to others	Sleep	Enjoyment of life		
3	3	4	3	2	3	4		
	American Chronic Pain Association Quality of Life Scale 6 • Works/volunteers limited hours • Takes part in limited social activities on weekends							



## Case #1 Baseline to 4-week summary

Labs (normal range)	Visit 1	Visit 2
hsCRP (0 – 3 mg/l)	64	49.25 \downarrow
Ferritin (15 – 150 ng/dl)	167	122 \downarrow
Fibrinogen (199 – 504 mg/dl )	611	512 👃
TNFa (0 – 8.1 pg/ml)	2.9	2.0 👃
ESR (0 – 32 mm/Hr)	13	44
BNP (0 – 100 pg/ml)	28.6	31.9
Omega-3 index (>/=5.5 %by weight)	3.7	4.1









Profile history & examination

Past medical & drug history Initial labs and tests

Management plan Week 4 followup

#### Complaints:

- Pain and difficulty in mobility in lower limbs
  - Ankles/ Feet 7/10 , 10/10 on certain motions
  - Tenderness on palpation of both areas on both ankles/ feet
  - · Limping and pain with ambulation.

### On Examination:

- Height: 5' 11"
- Weight: 244lbs
- BMI: 34.03kg/m<sup>2</sup>
- BP: 132/76 mm Hg
- Pulse: 87/min regular
- Temp: 98.7 (F)

#### Diagnosis:

- Osteoarthritis for several years
- Gout for few years
- Hypothyroidism for a few years
- · Hypertension for several years



Profile history & examination

Past medical & drug history

Initial labs and tests

Management plan Week 4 followup


## **Current therapy:**


- Tramadol
- Acetaminophen for arthritis
- Ibuprofen
- Nalfon
- Thyroid replacement
- Vitamin D3
- Podiapn
- DIM
- Iodine

## Family Medical History:

- Mother-SLE
- Father- Stroke
- Maternal Aunt- Lung and Breast Cancer.
















Profile history & examination

Past medical & drug history

Initial labs and tests

Management plan Week 4 followup

#### **Complaints:**

- Ankles/ Feet pain 2/10
  - No longer has 10/10 pain
  - Better ROM in both feet/ ankles

#### **Current therapy:**

• SPMs 6 soft gels/day

#### **On Examination:**


- BP: 130/82 mm Hg
- Pulse: 61/min regular
- Weight: 247lbs

## **Additional Notes:**

 Patient has been compliant with the protocol No adverse events to date


#### Management plan:

- Increase SPMs to 8 soft gels/day
  - Taper to maintenance dose of ~2 soft gels/day
- Continue to watch for and avoid dietary and environmental triggers of inflammation
  - obesity, body composition, glucose control, dietary sources, leaky gut, allergy, Infection
  - Utilize anti-inflammatory strategies as needed





for Clinical Nutrition




Profile history & examination		medical & and the second secon	Initial labs and tests	Managem plan	ent We	ek 4 follow- up	
Brief Pain	Inventor	у					
Worst Pain in past 24 hoursLeast Pain 24 hour20		st Pain in past 24 hours	Average Pain in past 24 hours	Pain now	Scale: 1 – no pain		17
		0	1	1		n as bad as you can Igine	U
Brief Pain Inventory							
			n interfered in you rfere) to 10 (comp		res)		
General activities	Mood	l Walking	g Normal work	Relations to others	Sleep	Enjoyment of life	
0	0	1					
			0	0	0	1	



## Case 2 Baseline to 4-week summary

Baseline score = 29 Week 4 score = 19

Labs (normal range)	Visit 1	Visit 2
hsCRP (0 – 3 mg/l)	5.15	4.11
Ferritin (15 – 150 ng/dl)	126	116
Fibrinogen (199 – 504 mg/dl )	434	361
TNFa (0 – 8.1 pg/ml)	3.9	2.8
ESR (0 – 32 mm/Hr)	4.0	7
BNP (0 – 100 pg/ml)	3.9	8.7
Omega-3 index (>/=5.5 %by weight)	3.0	4.2











## Case #1 Baseline to 4-week summary




American Chronic Pain Association – Quality of Life Scale				
Baseline	4 weeks			
<ul> <li>Score = 5</li> <li>Struggles but fulfills daily home responsibilities</li> <li>No outside activity</li> <li>Not able to volunteer or work.</li> </ul>	<ul> <li>Score = 6</li> <li>Works/volunteers limited hours</li> <li>Takes part in limited social activities on weekends</li> </ul>			



## Case 2 Baseline to 4-week summary





American Chronic Pain Association – Quality of Life Scale				
Baseline	4 weeks			
<ul> <li>Score = 10</li> <li>Go to work/volunteer each day.</li> <li>Normal daily activities each day.</li> <li>Have a social life outside of work.</li> <li>Take an active part in family life</li> </ul>	<ul> <li>Score = 10</li> <li>Go to work/volunteer each day.</li> <li>Normal daily activities each day.</li> <li>Have a social life outside of work.</li> <li>Take an active part in family life</li> </ul>			



## **Specialized Pro-resolving Mediators:** Innovation in Clinical Practice – New News in Patient Care

## Novel Solution and Pathway to Support Inflammatory Responses

- New Clinical Benefits to Resolve Inflammation
- Fills a Gap in Managing Inflammatory Responses

## Two Independent yet Complementary Solutions to Managing Inflammatory Conditions

- Not Blocking, inhibiting or suppressing inflammation
- 'Resolves' inflammation to avoid prolongation to to chronic health conditions

## Proprietary Nutritional Solutions

- Specialized Pro-resolving Mediators
- Standardized Level of Activity

## Clinical Uses with Superior Improvement in Ability to Resolve Inflammation

- Activates more effective resolution response
- Supports both normal inflammatory response AND its facilitated resolution



## **SPMs Utilization: Pre-Clinical Research is ongoing**



#### **Aspiration Pneumonia**

RvE1 decreased cytokines and PMN infiltration and enhances LXA4 formation and bacterial clearance



#### **Type 2 Diabetes**

RvD1 reduces macrophage accumulation, improved insulin sensitivity and promote healing of diabetic wounds RvE1 and RvD1 ameliorate insulin sensitivity and reduce hepatosteatosis

#### **Obesity**

RvE1 and PD1 reduced adipokines and fatty liver and RvD1 reduced proinflammatory cytokines and stimulates M2 macrophages in adipose



#### Vascular Disease

RvD1 inhibited platelet aggregation and leukocyte-endothelial cell interactions and reduced size of myocardial infarction

#### **Stroke**

PD1 inhibits leukocyte accumulation and reduces infarct volume

#### **Alzheimer's Disease**

PD1 reduces AB42 cleavage and protected neurons from apoptosis. LSx reduce NF-kB activation and stimulate alternative microglial cells



The Metagenics Healthcare Institute for Clinical Nutrition



#### Dry Eye RvE1analogue (RX-10045) reduce signs and symptoms

#### Retinopathy

SPMs protected against neovascularization

#### **Periodontitis**

LXs and RvE1 prevented PMN infiltration and connective tissue and bone loss

#### Arthritis

LXs inhibit edema formation and PMN influx, reduces TNF- $\alpha$  and LTB<sub>4</sub> levels RvD1 posseses anti-hyperalgesic effects and decreases TNF- $\alpha$  and IL-1 $\beta$  production

## For more information







## QUESTIONS?